Safety and Tolerability in Healthy Volunteers

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Annexon Biosciences
Annexon BiosciencesCA - Brisbane
2 programs
2
ANX005Phase 11 trial
ANX009Phase 11 trial
Active Trials
NCT03010046TerminatedEst. Jun 2018
NCT04535752CompletedEst. Jun 2021
Neuraly
NeuralyMD - Gaithersburg
1 program
1
NLY01Phase 11 trial
Active Trials
NCT03672604CompletedEst. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Annexon BiosciencesANX009
NeuralyNLY01
Annexon BiosciencesANX005

Clinical Trials (3)

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

Start: Oct 2020Est. completion: Jun 2021
Phase 1Completed

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

Start: Sep 2018Est. completion: Jul 2019
Phase 1Completed

Single Dose Study of ANX005 in Healthy Volunteers

Start: Dec 2016Est. completion: Jun 2018
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space